Takeaway
- Administration of liraglutide before cardiac surgery modestly improved post-operative cardiac function.
- Liraglutide improved heart rate and preserved left ventricular systolic function at post-operative follow‐up.
Why this matters
- Findings warrant further studies to evaluate the potential benefits of glucagon-like peptide-1 receptor agonists in patients undergoing cardiac surgery.
Study design
- A secondary analysis of the GLOBE trial included 261 adult patients who underwent cardiac surgery and randomly assigned them to receive liraglutide (n=129) or matching placebo (n=132).
- Funding: Novo Nordisk.
Key results
- The proportion of patients with normal left ventricular systolic function was higher in the liraglutide vs placebo group (68% vs 53%; difference, 15% [95% CI, 0-30%]; P=.049).
- Mean post-operative heart rate was significantly higher in the liraglutide vs placebo group (83 vs 77 beats/minutes; difference, 6 [95% CI, 3-8] beats/minutes; P<.001).
- Sinus rhythm and number of vasoactive/inotropic doses did not differ between both the groups.
- No significant difference was observed between both the groups in:
- troponin (P=.261);
- creatine kinase‐MB (P=.121);
- creatinine (P=.721);
- lactate (P=.697) levels;
- mean arterial pressure (P=.653); and
- right ventricular systolic function (P=.609).
Limitations
- Secondary analysis of a randomised clinical trial.
References
References
